Promising phase 2 results for new plaque psoriasis therapy
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...
1. Using the Physician Global Assessment (PGA), patients with acne or psoriasis recorded significant improvement in disease severity at 3-month ...
1. Treatment with brodalumab was shown to be safe and efficacious in patients with psoriatic arthritis or who previously failed ...
Originally published by Harvard Health. What Is It? Psoriasis is a chronic skin disorder that causes scaling and inflammation. Psoriasis may ...
1. Psoriasis severity was associated with an increased likelihood of uncontrolled hypertension. Evidence Rating Level: 2 (Good) Study Rundown: Psoriasis ...
1. The use of 120mg ixekizumab in a phase-III, open-label extension (OLE) trial showed improved Psoriasis Area and Severity Index ...
1. A history of hypertension for 6 or more years was linked with an increased risk of psoriasis in US ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.